1	2	3	4	
9	Ranitidine	M/s. Globe Organics	Do.	31-3-93
10	Amoxycillin Sodium	M/s. Duphar Interfran	Do.	31-3-92
11	Verapamil Hcl	M/s. Associated Drug Co. Pvt. Ltd.	Do.	28-2-94
12	Metroclopramide Hcl	M/s. Infar (I) Ltd.	Do.	31-1-94
13	Naproxen	M/s. Rallis India Ltd.	Do.	30-9-91
14	Theophylline	M/s. Pefco Industries Ltd.	Do.	December, 92
15	Betamethasone Disodium Phosphate	M/s. Glaxo India Ltd.	Do.	31-12-94
16	Ephedrine Hcl	M/s. Emmellen Biotech Pharma Ltd.	The company was issued rejection on the ground that the proposal did not fulfil the requisite conditions for grant of exemption from price control.	
17	Diclofence Sodium	M/s. Unique Chemicals	Under consideration of Expert Group on Technology Issues.	
18	Timolol Maleate	M/s. F.D.C. Ltd.;		
19	Cephalexin	M/s. Lupin Labs.		
20	Rifampicin	Do.		

Import of drugs and penultimates

4592. SHRI H. HANUMANTHAPPA: Will the PRIME MINISTER be pleased to state:

(a) whether it is a fact that Government Policy is encouraging more and more imports of drugs and penultimates/intermediates as the ratio parameters are totally faulty and ineffective;

(b) whether it is a fact that Government have not issued guidelines in respect of computation of value of production and consumption of indigenous bulk drugs;

(c) if so, the reasons therefor;

(d) whether it is also a fact that the value of imports of intermediates and penultimates are not covered in the ratio parameter;

(e) if so, whether it is a fact that import bill of imports of intermediates have gone up considerably;

(f) whether it is also a fact that number of units producing from basic stages have shifted to intermediates stages; and

(g) if so, the detail of instances came to the notice of Government and action taken thereon?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI CHINTA MOHAN): (a) No, Sir.

(b) and (c) The requirements for computing the value of production as well as of the consumption of indigenous bulk drugs have been announced in the Drug Policy, 1986 as given below:

I. (i) *Production*: The ratio between ex-factory value of production of bulk drugs and formulations should be as follows for non-FERA companies:

Turn Over	*Ratio Parameter*
Upto Rs. 10 crores	1 : 10
Beyond Rs. 10 crores	1 : 7

& upto Rs. 25 crores
Beyond Rs. 25 crores 1 : 5

(ii) *For FERA Companies*: ratio parameter will be 1:4 irrespective of level of turnover.

II. *Consumption*: The imported bulk drugs consumed shall not exceed 50% of the value of the indigenously produced bulk drugs.

(d) and (e) The ratio parameters governing imports for formulation activity are limited only to bulk drugs used to manufacture them. However, the imports of intermediates and penultimates are governed by the concept of basic stage manufacture of bulk drugs whereby such manufacture can only be undertaken from stages prescribed by Government.

(f) Such instances have not come to the notice of Government.

(g) Does not arise.

Price rise of erythrocin and vitamin C tablets

4593. SHRI H. HANUMANTHAPPA: Will the PRIME MINISTER be pleased to state:

(a) whether it is a fact that prices of price controlled products like erythrocin 500 mg (6's pack) and Vitamin C tablets 500 mg (10's pack) have risen by 103 per cent and 75 per cent respectively;

(b) what are the reasons for such steep price hikes after the announcement of DPCO, 1987 and what are the components of increase;

(c) what was the price of each before DPCO 1987 and what is the present price;

(d) whether it is a fact that normative calculation of rates of bulk drugs and other constituents have lead to such steep increases in prices;

(e) if so, what are the reasons and if not, what are the circumstances and basis of such steep increase; and

(f) what steps are proposed to investigate the matter and weed out the bureaucrats having nexus with the producers and the international forces?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI CHINTA MOHAN): (a) and (c) The requisite information, to the extent available, is given below:

Sl. No.	Name of Formulation	Pack Size	price before DPCO' 87 (Rs.)	Current price (Rs.)	%increase
1	Vit. C. 500mg.	10's Strip	3.29	6.32	92.09
2	Erythronmycin 500mg Tab.	6' Strip	16.25	32.26	98.52

(b) and (e) In a situation of rising cost of inputs certain amount of increase in the prices is inevitable if the availability has to be ensured. The increase is relatively more in those cases having high import context due to adjustment of exchange rate of rupee against major foreign currencies, partial convertibility of rupee, etc. However, as far as medicines under price control are concerned, Government is fixing/revising the prices as per the provisions of the Drug (Prices Control) Order, 1987 after careful scrutiny and in consultation with the Bureau of Industrial Costs and Prices. There has been an increase of 60.32 per cent and 89.86 per cent in the notified prices of bulk drug Erythromycin and Vit. C. after